Oral transmucosal fentanyl citrate (OTFC): Review;Citrato de fentanilo transmucosa oral (OTFC): Revision

Revista de la Sociedad Espanola del Dolor

Volumn 7, Issue 5, 2000, Pages 319-326

  Muriel, C ^a   Garcia Castano, M ^a   Yusta, G ^a   Sanchez Montero, Y F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Analgesia; Breakthrough pain; Cancer; Opioids; Oral transmucosal fentanyl citrate

Indexed keywords

ALFENTANIL; FENTANYL CITRATE; MORPHINE; REMIFENTANIL; SUFENTANIL CITRATE;

ANALGESIA; CANCER PAIN; CANCER PATIENT; CONTROL SYSTEM; DRUG ABSORPTION; DRUG EFFICACY; HUMAN; MOUTH MUCOSA; REVIEW;

EID: 0033895249     PISSN: 11348046     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. New routes of administatrion and new delivery systems of anesthetics
2. The use of oral transmucosal fentanyl citrate for painful procedures in children
3. Oral transmucosal fentanyl citrate for premedication of children undergoing laceration repair
4. Oral transmucosal fentanyl citrate premedication in patients undergoing outpatient dermatologic procedures
5. Oral transmucosal fentanyl citrate for analgesia and sedation in the emergency department
6. Oral transmucosal fentanyl premedication in children
7. Comparison of oral transmucosal fentanyl citrate and an oral solution of meperidine, diazapam, and atropine for premedication in children
8. The effects of oral transmucosal fentanyl cirate premedication on preoperative behavioral responses and gastric volume and acidity in children
9. Oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: A case report
10. Treatment of temporal variations in chronic cancer pain
11. Breakthrogh pain: Definition, prevalence and Characteristics
12. Brakthrough pain: Characteristics and impact in patients with cancer pain
13. Management of cancer pain
14. Breakthrough pain: Definiton, prevalence and characteristics
15. Breakthrough Pain in Cancer Patients: Characteristics, Prevalence, and Treatment
16. Cancer pain management: Newer perspectives on opioids and episodic pain
17. Opioid Pharmacotherapy in the Management of Cancer Pain. A Survey Of Strategies Used by Pain Physicians for the Selection of Analgesic Drugs and Routes of Administration
18. Morphine and metabolite behavior after different routes of morphine adminitratio: Demostration of the importance of the active metabolite morphine 6-glucoronide
19. Dose proportionality and pharmacokinetic of OTFC
20. Pharmacokinetics of intravenous morphine in patients anesthetized with enflurane-nitrous oxide
21. Intravenous fentanyl kinetics
22. The pharmacokinetics of alfentanil (R39209): A new opioid analgesic
23. The pharmacokinetics of sufentanil in surgical patients
24. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatients surgery
25. Absorpcion characteristics of transdermally administered fentanyl
26. The efficacy of transdermal fentanyl in the treatment of postoperative pain: A double blind comparison of fentanyl and placebo systems
27. Transdermal fentanyl: A review of its pharmacological properties and therapeutic efficacy in pain control
28. Opiod responsiveness
29. Withdrawal symptom during therapy with transdermal fentanyl (Fentanyl TTS)
30. Absorption and bioavaibility of oral transmucosa fentanyl citrate
31. Oral transmucosal etomidate in volunteers
32. Pitfalls in pharmacokinetics
33. OTFC: Randomized double -blind, placebo controlled trial for treatment of oral transmucosal fentanyl citrate in cancer pain
34. An open-label study of oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrogh cancer pain
35. Comparative clinical efficacy and safety of inmediate release and controlled hydromorfhone for chronic severe cancer pain
36. Dose tritation multicenter study of oral tansmucosal fentanyl citrate for the treatment of breacthrought pain in cancer patients using transdermal fentnyl for persit pain
37. A Review of oral transmucosal fentanyl citrate, potent, rapid an noninvasive opioid
38. Pharmacotherapeutic management of cancer pain: Current practice
39. Pharmacokinetics and Pharmacodynamic issues in the treatment fo breakthrough pain